E T Nguyen1, T Posas-Mendoza2, A M Siu3, H J Ahn4, S Y Choi4, S Y Lim5. 1. Lewis and Clark College, Portland, OR, USA. 2. Department of Internal Medicine, University of Hawaii, Honolulu, HI, USA. 3. Hawaii Pacific Health Research Institute, Honolulu, HI, USA. 4. Department of Complementary and Integrative Medicine, University of Hawaii, Honolulu, HI, USA. 5. Hawaii Pacific Health, Bone and Joint Center, Straub Clinic, 888 S. King Street, Honolulu, HI, 96813, USA. limsianyik@gmail.com.
Abstract
We evaluated osteoporosis treatment and DEXA utilization rates of patients who were admitted for hip fracture in a single healthcare system in Hawaii from 2015 to 2016. We found that osteoporosis treatment and DEXA utilization rates were low, highlighting a critical gap in osteoporosis care after admission for hip fracture. INTRODUCTION: The objective of this study was to evaluate osteoporosis care after an admission for hip fracture at three community hospitals within a single healthcare system in Hawaii. METHODS: A retrospective chart review was conducted (n = 428) of patients ≥ 50 years and hospitalized for hip fractures between January 1, 2015, and May 31, 2016, at three major hospitals within Hawaii Pacific Health, a large healthcare system in Hawaii. Basic demographics were collected, and medications prescribed were quantified and described within 1 year of hip fracture. Logistic regression was used to evaluate the association between collected variables and the odds of osteoporosis treatment. RESULTS: Only 115 (26.9%) patients were prescribed a medication for osteoporosis as a secondary prevention within a year of hospitalization for hip fracture. DEXA scans were performed in 137 (32.0%) patients. Most of the treated patients were prescribed oral bisphosphonates. Treatment facility, female gender, and higher BMI were found to be predictive factors for osteoporosis treatment. CONCLUSION: The use of osteoporosis medication for secondary prevention after admission for hip fracture in Hawaii is low. Efforts need to be made to improve treatment rates, especially among males.
We evaluated osteoporosis treatment and DEXA utilization rates of patients who were admitted for hip fracture in a single healthcare system in Hawaii from 2015 to 2016. We found that osteoporosis treatment and DEXA utilization rates were low, highlighting a critical gap in osteoporosis care after admission for hip fracture. INTRODUCTION: The objective of this study was to evaluate osteoporosis care after an admission for hip fracture at three community hospitals within a single healthcare system in Hawaii. METHODS: A retrospective chart review was conducted (n = 428) of patients ≥ 50 years and hospitalized for hip fractures between January 1, 2015, and May 31, 2016, at three major hospitals within Hawaii Pacific Health, a large healthcare system in Hawaii. Basic demographics were collected, and medications prescribed were quantified and described within 1 year of hip fracture. Logistic regression was used to evaluate the association between collected variables and the odds of osteoporosis treatment. RESULTS: Only 115 (26.9%) patients were prescribed a medication for osteoporosis as a secondary prevention within a year of hospitalization for hip fracture. DEXA scans were performed in 137 (32.0%) patients. Most of the treated patients were prescribed oral bisphosphonates. Treatment facility, female gender, and higher BMI were found to be predictive factors for osteoporosis treatment. CONCLUSION: The use of osteoporosis medication for secondary prevention after admission for hip fracture in Hawaii is low. Efforts need to be made to improve treatment rates, especially among males.
Entities:
Keywords:
Hip fracture; Hospitalization; Osteoporosis; Secondary prevention
Authors: C S Colón-Emeric; R Sloane; W G Hawkes; J Magaziner; S I Zimmerman; C F Pieper; K W Lyles Journal: Am J Med Date: 2000-09 Impact factor: 4.965
Authors: D Marsh; K Akesson; D E Beaton; E R Bogoch; S Boonen; M-L Brandi; A R McLellan; P J Mitchell; J E M Sale; D A Wahl Journal: Osteoporos Int Date: 2011-05-24 Impact factor: 4.507
Authors: Catherine MacLean; Sydne Newberry; Margaret Maglione; Maureen McMahon; Veena Ranganath; Marika Suttorp; Walter Mojica; Martha Timmer; Alicia Alexander; Melissa McNamara; Sheetal B Desai; Annie Zhou; Susan Chen; Jason Carter; Carlo Tringale; Di Valentine; Breanne Johnsen; Jennifer Grossman Journal: Ann Intern Med Date: 2007-12-17 Impact factor: 25.391
Authors: Luke Taylor; Chieko Kimata; Andrea M Siu; Samantha N Andrews; Prashant Purohit; Melissa Yamauchi; Andras Bratincsak; Russell Woo; Cass K Nakasone; Sian Yik Lim Journal: Osteoporos Sarcopenia Date: 2021-09-06
Authors: M K Skjødt; S Khalid; M Ernst; K H Rubin; D Martinez-Laguna; A Delmestri; M K Javaid; C Cooper; C Libanati; E Toth; B Abrahamsen; D Prieto-Alhambra Journal: Osteoporos Int Date: 2020-03-17 Impact factor: 4.507
Authors: M K Skjødt; M T Ernst; S Khalid; C Libanati; C Cooper; A Delmestri; K H Rubin; M K Javaid; D Martinez-Laguna; E Toth; D Prieto-Alhambra; B Abrahamsen Journal: Osteoporos Int Date: 2021-03-15 Impact factor: 4.507